BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives $138.25 Consensus Target Price from Brokerages

BioNTech SE Sponsored ADR (NASDAQ:BNTX) has earned an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the company, Marketbeat reports. Four analysts have rated the stock with a hold recommendation, thirteen have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $137.86.

Several research firms recently issued reports on BNTX. Citigroup reiterated a “buy” rating and set a $140.00 price target (down previously from $145.00) on shares of BioNTech in a research report on Tuesday, May 6th. The Goldman Sachs Group began coverage on shares of BioNTech in a research report on Thursday, May 29th. They set a “neutral” rating and a $110.00 price target on the stock. HC Wainwright reduced their price target on shares of BioNTech from $145.00 to $138.00 and set a “buy” rating on the stock in a research report on Monday. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Finally, Leerink Partners set a $112.00 price objective on shares of BioNTech in a research note on Monday, June 2nd.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Banque Cantonale Vaudoise acquired a new stake in BioNTech in the first quarter valued at $36,000. Jones Financial Companies Lllp lifted its position in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its position in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after acquiring an additional 700 shares in the last quarter. Allianz SE purchased a new stake in shares of BioNTech in the fourth quarter valued at $90,000. Finally, Banque Transatlantique SA purchased a new stake in shares of BioNTech in the first quarter valued at $80,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Stock Down 1.3%

Shares of BNTX opened at $104.97 on Friday. BioNTech has a 52 week low of $76.53 and a 52 week high of $131.49. The firm has a market cap of $25.23 billion, a P/E ratio of -30.87 and a beta of 1.29. The firm’s 50-day simple moving average is $101.59 and its 200 day simple moving average is $107.87. The company has a debt-to-equity ratio of 0.01, a quick ratio of 10.02 and a current ratio of 10.18.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.